A novel five-antibody immunohistochemical test for subclassification of lung carcinoma

• Published in: Modern pathology Vol. 22; no. 8; pp. 1032 - 1043
• Main Authors: Ring, Brian Z, Seitz, Robert S, Beck, Rodney A, Shasteen, William J, Soltermann, Alex, Arbogast, Stefanie, Robert, Francisco, Schreeder, Marshall T, Ross, Douglas T
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.08.2009; Elsevier Limited
• Subjects: Adenocarcinoma - classification; Adenocarcinoma - pathology; Aged; Algorithms; Antibodies; Biomarkers, Tumor - analysis; Biopsy; Cancer; Carcinoembryonic Antigen - biosynthesis; Carcinoma, Squamous Cell - classification; Carcinoma, Squamous Cell - pathology; Chemotherapy; Classification; Clinical trials; DNA-Binding Proteins - biosynthesis; Female; Gene expression; Genomics; GPI-Linked Proteins; Histology; Humans; Immunohistochemistry - methods; Keratin-5 - biosynthesis; Keratin-6 - biosynthesis; Kinases; Laboratory Medicine; Large Neutral Amino Acid-Transporter 1 - biosynthesis; Lung Neoplasms - classification; Lung Neoplasms - pathology; Male; Medicine; Medicine & Public Health; Middle Aged; Morphology; Mucin-1 - biosynthesis; Neoplasm Staging; original-article; Pathology; Patients; R&D; Research & development; Stains & staining; Thyroid gland; Tissue Array Analysis; Trans-Activators - biosynthesis; Transcription factors; Transcription Factors - biosynthesis; Tumor Suppressor Proteins - biosynthesis; Tumors; United States > US; bevacizumab; adenocarcinoma; histological type; lung carcinoma; squamous cell carcinoma

Malignant epithelial lung carcinoma can be subclassified by histology into several tumor types, including adenocarcinoma and squamous cell carcinoma. The need for a uniform method of classifying lung carcinomas is growing as clinical trials reveal treatment and side effect differences associated wit...